Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Asian Stocks Mixed Over Fading Vaccine Optimism

Published 11/16/2020, 10:29 PM
Updated 11/16/2020, 10:33 PM
© Reuters.

By Gina Lee

Investing.com – Asia Pacific stocks were mixed on Tuesday morning, giving up some earlier gains after optimism over the latest positive COVID-19 vaccine news fizzled.

Moderna Inc (NASDAQ:MRNA) became the latest pharmaceutical company to report a positive development when t said on Monday that its candidate mRNA-1273 had a 94.5% efficacy rate from the results of a large, late-stage phase III COVE study. The news follows Pfizer Inc's (NYSE:PFE) announcement during the previous week that its candidate, BNT162b, that is being co-developed with Germany’s BioNTech (F:22UAy), prevented more than 90% of symptomatic infections.

Moderna’s news saw the company’s shares climbed up to 15% and helped U.S. shares see record highs over hopes of a quick economic recovery.

As was the case after the Pfizer announcement, shares, particularly those for value and cyclical sectors hit by the pandemic such as aviation, initially rose over hopes of a global economic recovery and the possibility of re-openings in 2021.

However, worries over vaccine productions and delivery remain. The ever-increasing number of COVID-19 cases globally, particularly in Europe and the U.S., also dampened the enthusiasm.

“We might be transitioning from a defensive bull market to a more cyclically offensive one, but more clarity is required in terms of when social mobility will normalize. That isn’t clear yet. The euphoria created by the presidential election result and the vaccine announcement will give way to a more sober analysis of how long and smooth the road to recovery will be,” AXA Investment Managers Core Investments chief investment officer Chris Iggo said in a note.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Other investors remained more optimistic.

“This is a continuation of what we saw last week as the vaccine being a catalyst for a rotation into cyclical sectors such as energy, financials, and defense with expectations for renewed demand and travel … the light switch has really been turned on and this is the real deal unlike some months back,” Great Hill Capital managing member Thomas Hayes told Reuters

Japan’s Nikkei 225 edged up 0.20% by 11:27 PM ET (3:27 AM GMT).

South Korea’s KOSPI edged up 0.14%. Prime Minister Sye Kyun Chung announced tighter social distancing rules for the greater Seoul area earlier in the day. The country reported 230 COVID-19 cases as of midnight on Monday, the highest number since early September.

The increase to Level 1.5 means banning public gatherings of 100 people or more, limiting religious services and audiences at sporting events to 30% capacity, and requiring high-risk facilities, including clubs and karaoke bars, to increase the distance among guests.

In Australia, the ASX 200 was up 0.33% while Hong Kong’s Hang Seng Index inched down 0.01%.

China’s Shanghai Composite edged down 0.19% and the Shenzhen Component slid 1.22%.

On the data front, the U.S. will release retail sales and industrial production data for October later in the day, following China’s release of its own positive October retail sales and industrial production data on Monday.

Latest comments

🤔🤔🤔
Not so simple as 123....it needs time and the virus is evolving mutating...
Mixed? Theyre down cuh
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.